Tolerability and Toxicity of Topically Applied Nepafenac 0.3% vs Ketorolac 0.5%

Trial Profile

Tolerability and Toxicity of Topically Applied Nepafenac 0.3% vs Ketorolac 0.5%

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Mar 2017

At a glance

  • Drugs Nepafenac (Primary) ; Ketorolac
  • Indications Ocular inflammation
  • Focus Adverse reactions
  • Most Recent Events

    • 03 Mar 2017 Status changed from recruiting to completed.
    • 29 Apr 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top